Tychon Bioscience

Tychon Bioscience was a biotechnology company focused on the development of a proprietary platform for creating multispecific antibodies. The company's technology, originated from research at the Icahn School of Medicine at Mount Sinai and Emory University, aimed to produce therapies that could simultaneously engage multiple biological targets to treat complex diseases like cancer. By leveraging its platform, Tychon sought to improve the efficacy and safety profiles of traditional monoclonal antibody treatments. The platform was designed to enable the rapid discovery of novel biologics with enhanced precision and potency. In January 2021, Tychon Bioscience was acquired by Agenus for approximately $20 million in stock plus potential milestones. This acquisition allowed Agenus to integrate Tychon's multispecific capabilities into its broader immuno-oncology portfolio.